The 2026 cumulative-dose trial studied 91 adolescents and young adults with acne, not adults aged 25-55 with persistent acne. It found no added benefit from 150 mg/kg over the standard 120 mg/kg. Isotretinoin is a prescription drug that shrinks oil glands and clears severe acne. Cumulative dose means the total drug received during a course, divided by body weight.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the dose trial tested
- Who the results best fit
- Who was outside the trial
- How adults can use the finding
What the dose trial tested
UNSW investigators led by Prof. Dedee Murrell assigned 91 patients to 120 mg/kg or 150 mg/kg.
They tracked change in lesion counts, acne severity, and relapse at 12 months, as described in The Limbic report on the UNSW trial. Relapse was 26.7% with 120 mg/kg and 32.3% with 150 mg/kg after 12 months. The Limbic, reporting the UNSW trial, presents this as no added relapse prevention from the higher dose.
Who the results best fit
The dose trial centered on teenagers and young adults starting a standard course. That age focus matches the large background cohort informing dose expectations, which included 19,907 patients aged 12 or older treated for at least four months.
In that JAMA Dermatology cohort, reported by Medical Dialogues, the mean age was 20.6 years and 52.8% were female. Female sex raised relapse risk yet lowered retrial, so young women were well represented while older adults with lasting acne were a minority.
Who was outside the trial
Adults with acne that has continued since the teen years fall outside the dose trial. A separate adult population included 58 people aged 25-55 with low-grade acne persisting since adolescence, nearly 90% women, studied on 5 mg per day versus placebo, according to the MDedge report on the adult low-dose trial. That group differs in ways that matter for care:.
- age 25-55, rather than adolescent or young adult
- low-grade but persistent disease, rather than a first standard course
- mainly women, with pregnancy prevention and tolerability as central issues
- very-low daily dosing, rather than 120 mg/kg versus 150 mg/kg
How adults can use the finding
Adults with persistent acne can generally aim for the standard 120-mg/kg total and adjust daily dosing for tolerability. Dermatology Times, synthesizing the UNSW result with the JAMA Dermatology data, points away from pushing to 150 mg/kg only to prevent relapse.
For a clinic visit, focus on personal dose history and tolerance. Ask what cumulative dose you already received, which daily dose you tolerated, and whether side effects forced breaks. Bring your weight, prior dose, side effects, and relapse history to that visit.
You Might Also Like
- Treatment Response in the 2026 Cumulative Isotretinoin Dose Trial: How Adults With Persistent Acne Can Compare Treatment Options
- Low-Dose Isotretinoin Side Effects in the 2026 Fish Oil Trial: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Recovery and Pigment Safety in the 2026 Split-Face Acne Scar Trial: Who Was Studied and Who Was Not for People With Boxcar Acne Scars